Camurus Ab (CAMRF) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Camurus Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.824 -- 00:00:07.031 Thank you, Einar, and hello, everyone. Welcome to our second quarter earnings call. 00:00:07.031 -- 00:00:10.753 Here are our forward-looking statements. 00:00:10.795 -- 00:00:15.940 So the agenda for our call today is a summary of highlights in the quarter, followed 00:00:15.940 -- 00:00:19.564 by financial and commercial performance reviews, 00:00:19.564 -- 00:00:25.290 then an update on the pipeline and business development before finishing off with Q&A. 00:00:25.290 -- 00:00:30.371 So with me to provide the financial update is John Garay, CFO, Also 00:00:30.371 -- 00:00:35.859 present are Richard Jameson, Chief Commercial Officer, and Anders Walshorp, incoming 00:00:35.859 -- 00:00:37.859 CFO. 00:00:38.563 -- 00:00:44.612 Camurus had a successful second quarter with good performances across our business. 00:00:44.612 -- 00:00:49.760 Financially, we delivered all-time record revenues, high profitability, 00:00:49.760 -- 00:00:56.056 further strengthening our cash position for planned expansions and pipeline investments. 00:00:56.056 -- 00:01:00.522 And on the corporate side, we entered a strategically important license agreement for 00:01:00.522 -- 00:01:05.530 long-acting incretins with Eli Lilly, as you know, a world leader in cardiometabolic 00:01:05.530 -- 00:01:07.132 disease. 00:01:07.132 -- 00:01:12.319 Commercially, our teams continued execution with Bovidal growing in Europe and the rest 00:01:12.319 -- 00:01:18.087 of the world, Brixhadi regaining momentum after a quiet first quarter, 00:01:18.087 -- 00:01:22.600 and in the R&D pipeline, key milestones were achieved. 00:01:22.600 -- 00:01:28.811 Of course, the EU approval of Oxisa for the treatment of Acromegaly was a clear highlight, 00:01:28.811 -- 00:01:34.181 which...